CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.11
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company with businesses including CSL Behring, CSL Seqirus and CSL Vifor, focused on plasma therapies, vaccines and specialty medicines. Remove dated market-cap and return statistics.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$181.91

28 Sep
2026

4.960

OPEN

$177.00

2.80%

HIGH

$181.91

1,063,237

LOW

$175.38

TARGET
$167.673 -7.8% downside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) 881.0 xxx
DPS (cps) 425.6 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 20.7 xxx
Dividend Yield 2.3% xxx
Div Pay Ratio(%) 48.3% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.67%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.29

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/09 - (franking ex-div 227.70c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic 700.2663.2691.8834.6957.6-789.7
DPS All 293.9318.1362.9397.4452.2405.4
Sales/Revenue 13,765.9 M14,467.5 M19,583.6 M22,414.6 M23,825.3 M23,166.3 M
Book Value Per Share 2,452.94,400.84,916.45,379.96,093.14,459.7
Net Operating Cash Flow 4,857.0 M3,624.4 M3,866.5 M4,217.4 M5,498.5 M5,182.8 M
Net Profit Margin 23.14 %21.49 %17.03 %17.99 %19.46 %-16.43 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed 30.85 %19.21 %14.85 %16.22 %16.70 %-14.97 %
Return on Invested Capital 17.62 %13.24 %9.64 %9.68 %10.46 %-9.37 %
Return on Assets 13.66 %9.51 %6.97 %7.24 %7.92 %-7.00 %
Return on Equity 30.85 %19.21 %14.85 %16.22 %16.70 %-14.97 %
Return on Total Capital 22.31 %14.56 %10.85 %12.22 %12.77 %13.23 %
Free Cash Flow ex dividends 1,968.1 M704.8 M428.1 M1,103.2 M2,456.6 M2,145.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt 631 M6,535 M1,585 M1,413 M1,227 M1,648 M
Long Term Debt 7,104 M7,509 M16,784 M16,829 M16,318 M14,079 M
Total Debt 7,735 M14,045 M18,369 M18,242 M17,545 M15,727 M
Goodwill - Gross 1,583 M1,727 M12,137 M12,097 M12,306 M9,187 M
Cash & Equivalents - Generic 2,409 M15,177 M2,326 M2,481 M3,291 M2,184 M
Price To Book Value 11.636.115.645.493.932.57

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex 2,235.6 M1,720.3 M2,515.2 M1,919.5 M1,541.0 M1,884.5 M
Capex % of Sales 16.24 %11.89 %12.84 %8.56 %6.47 %8.13 %
Cost of Goods Sold 6,119 M6,792 M10,119 M11,503 M12,186 M12,113 M
Selling, General & Admin. Exp & Other 3,510 M3,734 M5,105 M5,263 M5,415 M5,134 M
Research & Development 1,343 M1,594 M1,836 M2,182 M2,098 M1,805 M
Investments - Total 29 M586 M260 M244 M310 M222 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxx xx xxxxxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

02/09/2026

1

Overweight

$182.00

(04/09/2026)

0.05%

CSL has reached an agreement with the US government to provide Medicaid access to certain medicines at most-favoured-nation pricing. This matches the lowest prices available in other developed countries, Morgan Stanley highlights.

The broker assumes CSL's relevant exposure is haemophilia, for which it forecasts around US$1.5bn of global revenue in FY27.

It's believed around US$75m of revenue could be exposed to lower pricing but the analysts expect only a modest impact on FY27 profit under various price-reduction scenarios.

Management also does not expect the agreements to have a material financial impact in FY27.

Overweight and $172 target retained. Industry view: In Line.

FORECAST
Morgan Stanley forecasts a full year FY27 EPS of 898.76 cents.
Morgan Stanley forecasts a full year FY28 EPS of 962.16 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

20/08/2026

2

Upgrade to Overweight from Neutral

$207.00

13.79%

Jarden upgrades CSL to Overweight from Neutral with its target price increased to $207.00 from $191.00 following an FY26 result that demonstrated better-than-expected operating profit across every division.

The analyst highlights that, although a step-up in sales force investment weighed on FY26 net profit after tax, constant currency performance landed marginally ahead of guidance.

The broker's estimates factor in restored confidence through FY27 guidance, which anticipates mid-single-digit growth for Behring and mid-to-high single-digit growth for immunoglobulin, easing prior fears regarding plasma collection.

Management expects low single-digit growth for Seqirus, whereas Vifor continues to face headwinds resulting in a projected -25% revenue decline for its portfolio in FY27.

The valuation is supported by a better overall growth outlook, cost-out initiatives, sales force reinvestment, and a US$1.1b share buyback.
Access Extra Coverage Research History >

CSL STOCK CHART

FNArena News on CSL

1
Rudi’s View: Ampol, BlueScope, Evolution, Infratil, Ramelius & More

Sep 24 2026 - Rudi's View
2
Rudi’s View: Australia’s Most Unloved Buy-Rated Stocks

Sep 23 2026 - Rudi's View
3
Weekly Ratings, Targets, Forecast Changes – 18-09-26

Sep 21 2026 - Weekly Reports
4
Treasure Chest: Healthcare Upgrades

Sep 17 2026 - Treasure Chest
5
Rudi’s View: Post-August Stock Picks & Best Buys

Sep 10 2026 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Telix Aims For A Strategic Isotope Supply Chain

Sep 24 2026 - Australia
2
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
3
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
4
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
5
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
6
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
7
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
8
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
9
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
10
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals